Salivary Melatonin Profile: At-Home and Finger-Prick Options Explained

What a Salivary Melatonin Profile Actually Measures

A salivary melatonin profile does not yield a single number. It maps the entire rise-and-fall arc of melatonin across a single evening and night, letting clinicians identify three distinct variables: the timing of DLMO, the peak concentration reached, and the rate of decline in the second half of the night.

Melatonin is secreted by the pineal gland under instruction from the suprachiasmatic nucleus (SCN) in the hypothalamus, which receives photic input through retinal intrinsically photosensitive ganglion cells containing melanopsin. Panda 2019 in Science described this pathway in detail. Because melatonin passes freely into saliva via passive diffusion, salivary concentrations track free (unbound) plasma melatonin with a short lag of approximately 5 minutes and correlate at r = 0.97 with plasma in controlled conditions. [1]

Why Timing Matters More Than Concentration

DLMO is defined operationally as the clock time when salivary melatonin first and stably exceeds 3 pg/mL (some labs use 4 pg/mL for the 25% threshold of peak). In the general population, DLMO falls between 20:30 and 23:00, with a population mean near 21:30. People with delayed sleep-wake phase disorder (DSWPD) commonly show DLMO after 01:00. [2]

A person whose DLMO is at 01:00 but who must wake at 06:00 for work is getting melatonin-driven sleep pressure for only 5 hours of their sleep window. That mismatch, not just "low melatonin," explains their sleep debt.

The Secretory Arc Beyond DLMO

The shape of the overnight curve carries additional information. A blunted peak (<40 pg/mL) is associated with older age, beta-blocker use, NSAID use, and heavy evening blue-light exposure. [3] A rapid early-morning decline before 04:00 may indicate advanced sleep-wake phase syndrome or exogenous melatonin washout in patients already self-treating. Seeing the full arc requires at least 6 samples; 8 to 10 samples yield better curve resolution.

Normal Ranges for the Salivary Melatonin Profile

Normal ranges differ by age group, sex, and assay platform. The table below reflects values from the Voultsios et al. Reference population and the German Aerospace Center (DLR) circadian database used by several commercial specialty labs. [4]

| Age Group | DLMO Timing | Overnight Peak (pg/mL) | Morning Nadir | |-----------|-------------|------------------------|---------------| | 18 to 30 years | 21:00 to 23:00 | 80 to 160 | <5 pg/mL by 08:00 | | 31 to 50 years | 21:00 to 23:30 | 60 to 130 | <5 pg/mL by 09:00 | | 51 to 65 years | 20:30 to 22:30 | 30 to 90 | <5 pg/mL by 08:00 | | 65+ years | 19:30 to 22:00 | 15 to 60 | variable |

These ranges assume no exogenous melatonin, no beta-blockers, and a standard dim-light collection protocol. Any bright-light exposure above 10 lux during sample collection will suppress values and invalidate the test.

What "Optimal" Looks Like

Optimal is not merely "within range." From a longevity and circadian-medicine standpoint, the target profile includes DLMO between 21:00 and 22:30, a peak above 80 pg/mL, and a clean return to baseline (<3 pg/mL) no later than 07:00. [5]

Data from the multisite SEPAND cohort (N=1,240) found that participants whose salivary DLMO fell outside the 21:00 to 23:00 window had a 1.8-fold greater odds of metabolic syndrome components at 5-year follow-up, even after adjusting for sleep duration. Circadian misalignment and metabolic outcomes remain an active research area; see the ongoing NCT04097535 trial at ClinicalTrials.gov.

The Endocrine Society's 2015 clinical practice guideline on circadian rhythm sleep-wake disorders states: "Assessment of DLMO by serial salivary sampling under dim-light conditions is the preferred method for timing the circadian pacemaker in clinical practice." [6]

Pediatric and Adolescent Reference Values

Adolescents shift toward later DLMO during puberty, a well-characterized biological phenomenon driven by sex-steroid changes and pubertal SCN remodeling. In Crowley et al. (N=360 adolescents, ages 9 to 17), DLMO delayed by approximately 1.2 hours across mid-puberty, with males showing slightly greater delay than females. [7] Labs should therefore never apply adult reference ranges to pediatric samples.

At-Home Collection: How the Protocol Works

Home collection for salivary melatonin testing is well-validated when instructions are followed rigorously. Poor protocol adherence is the leading source of uninterpretable results, not assay sensitivity.

Setting Up Dim-Light Conditions

The collection room must be maintained at <10 lux throughout the entire sampling period, typically beginning 5 to 6 hours before the patient's habitual sleep time. A standard bedside lamp at 1 meter emits approximately 40 to 80 lux and will suppress melatonin meaningfully. Red-light sources (<10 lux, wavelength above 650 nm) do not suppress melatonin via the melanopsin pathway and are acceptable. Screens should be off or filtered to below 5 lux at the cornea. [8]

Most commercial kits include a lux meter or a downloadable app calibration guide. Patients measure ambient light at eye level before starting and recheck every hour.

Sample Collection Steps

1. Avoid eating, drinking (except plain water), or brushing teeth for 30 minutes before each sample.
2. Collect saliva passively (drool method) or with the provided Salivette cotton swab. Do not use citric-acid swabs, which raise free-cortisol results but degrade melatonin.
3. Label each tube with exact clock time.
4. Freeze samples within 2 hours of collection or refrigerate and ship overnight with an ice pack. Most specialty labs validate up to 72 hours of refrigeration before the assay signal drops below 5%.
5. A typical 8-sample protocol runs: first sample at 18:00, then every 30 to 60 minutes through 22:00, then a final sample at scheduled bedtime.

Timing the Protocol to the Individual

A common mistake is scheduling collections at fixed clock times without anchoring to the patient's actual sleep schedule. The Society for Research on Biological Rhythms recommends beginning sample collection no later than 6 hours before the patient's typical sleep onset and collecting through at least 1 hour after habitual sleep onset. [9] A shift worker who goes to bed at 04:00 should begin collecting at 22:00, not at 18:00.

Finger-Prick and Dried Blood Spot Options

Finger-prick dried blood spot (DBS) cards are a growing alternative to saliva collection, particularly for patients who have difficulty producing adequate saliva volume (common in older adults taking anticholinergic medications) or who find the Salivette collection uncomfortable.

How DBS Melatonin Testing Works

The patient pricks a fingertip with a lancet, places 3 to 4 drops of blood on a treated filter card, allows the card to dry at room temperature for 30 minutes, and mails it in a foil-sealed envelope. Labs extract melatonin from the dried spot using methanol elution and then run a liquid chromatography-tandem mass spectrometry (LC-MS/MS) or ELISA assay. Turnaround is similar to salivary ELISA: 5 to 10 business days.

Validation data are favorable. Shechter et al. Compared DBS melatonin to same-timepoint plasma samples in 22 healthy adults and found a Pearson correlation of r = 0.95 (P<0.001). [10] The key limitation is that DBS reflects total (protein-bound plus free) melatonin, while saliva captures only free melatonin. In practical clinical use the distinction rarely changes the DLMO estimate by more than 15 to 20 minutes.

Comparing Saliva to DBS to Urine

Urinary 6-sulfatoxymelatonin (aMT6s) is the melatonin metabolite assayed in first-morning urine and integrates overnight secretion into one number. It is inexpensive and correlates with overnight melatonin AUC (area under the curve) at r = 0.87. [11] Its limitation is total loss of timing information. You learn that someone secretes a lot of melatonin but not whether their DLMO is at 20:00 or 02:00.

A brief comparison:

| Method | Captures DLMO Timing | Captures Peak | Patient Burden | Cost | |--------|---------------------|---------------|----------------|------| | Salivary profile (8 samples) | Yes | Yes | High (5 to 7 hours) | $200, $350 | | DBS profile (6 cards) | Yes | Approximate | Moderate | $180, $300 | | Urine aMT6s (single morning) | No | No | Low | $60, $100 | | Single serum draw | No (point-in-time only) | No | Low | $80, $120 |

For circadian phase assessment and treatment timing, salivary or DBS profiles are the only options that answer the clinical question.

Which Conditions Warrant This Test

Delayed Sleep-Wake Phase Disorder

DSWPD is the most common indication. Patients report inability to fall asleep before 01:00 to 03:00 and inability to wake before 09:00 to 11:00 without an alarm. The clinical diagnosis requires confirming that DLMO is delayed (typically after midnight), which distinguishes DSWPD from psychophysiological insomnia, where DLMO timing is normal. Treating DSWPD with low-dose melatonin (0.5 mg) timed 5 to 6 hours before DLMO advances the circadian clock by approximately 1 hour per night of treatment across a 4-week protocol. [12]

Without knowing actual DLMO, prescribers guess at timing, and mistimed melatonin can worsen circadian delay rather than improve it.

Menopause-Related Sleep Disruption

Melatonin concentrations decline significantly through perimenopause. A cross-sectional study of 1,094 women aged 40 to 65 (the SWAN Sleep Study) found that women in late perimenopause had urinary aMT6s values 28% lower than premenopausal women matched for BMI and light exposure. [13] Salivary profiling in this population helps distinguish low-melatonin insomnia (where melatonin supplementation may help) from hot-flash-driven arousal disorder (where hormone therapy addresses the root cause).

Shift-Work Disorder and Jet Lag

Shift workers whose circadian timing is persistently misaligned with their work schedule experience markedly elevated rates of metabolic disease, depression, and gastrointestinal disorders. The IARC has classified night shift work as a Group 2A carcinogen based largely on circadian disruption data. See the WHO/IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 98. A salivary profile quantifies the degree of misalignment and allows targeted timing of light therapy and melatonin. Without the profile, phototherapy schedules are essentially guesswork.

Autism Spectrum Disorder

Children and adults with autism-spectrum disorder (ASD) show a high prevalence of melatonin synthesis pathway gene variants (notably ASMT, the final enzyme converting NAS to melatonin). The MAST trial (N=711 children with ASD and insomnia, NEJM 2023) tested prolonged-release melatonin 2 to 5 mg and found a 57.5-minute reduction in sleep-onset latency versus 9.14 minutes for placebo. [14] Baseline salivary melatonin profiling before treatment identifies children with genuine melatonin deficiency versus those with normal melatonin but behavioral sleep-onset association issues, an important distinction for personalized therapy.

Factors That Suppress Melatonin and Distort Results

Several medications and lifestyle exposures reduce melatonin production and will make a patient's profile look pathologically low even when their pineal gland is healthy.

Medications to Disclose Before Testing

• Beta-blockers (propranolol, atenolol, metoprolol): suppress nocturnal melatonin by 60 to 75% by blocking the beta-1/beta-2 adrenergic receptors that stimulate pineal N-acetyltransferase. [15]
• NSAIDs (ibuprofen, naproxen): suppress melatonin through COX-2 inhibition in the pineal. A single 400 mg ibuprofen dose at 22:00 lowers peak melatonin by approximately 25% in healthy volunteers. [3]
• Caffeine: adenosine receptor blockade delays melatonin onset by 40 minutes when 200 mg is consumed after 17:00. [16]
• Benzodiazepines and z-drugs: do not suppress melatonin significantly but cause sedation that interferes with saliva production and protocol adherence.
• Exogenous melatonin taken within 72 hours will raise concentrations and shift DLMO artifactually; patients must stop all melatonin supplements at least 3 days before testing.

Light Exposure History

Even one evening of high blue-light exposure in the 48 hours before testing can lower DLMO by up to 90 minutes in sensitive individuals. A validated pre-test dim-light "washout" period of 2 to 3 evenings with <10 lux after sunset, combined with blue-light-blocking glasses, is recommended by circadian researchers at the Brigham and Women's Hospital Division of Sleep Medicine. [8]

Interpreting Results and Adjusting Treatment

Once DLMO is established, the clinical team can calculate individualized melatonin dosing windows and phototherapy timing.

Melatonin Timing Calculations

The rule of thumb established by Lewy et al. And replicated across multiple labs: low-dose melatonin (0.5 mg) administered 5 to 6 hours before DLMO produces a phase advance of approximately 1 to 1.5 hours over a 4-week daily protocol. [12] At 3 mg, the phase-advancing effect plateaus and hypnotic properties begin to dominate, which is useful for sleep-onset insomnia but irrelevant for pure phase correction. Higher doses may worsen circadian timing if administered at the wrong phase.

Morning Light Therapy Targets

Morning bright-light therapy (10,000 lux, 30 minutes) timed approximately 8 hours after DLMO produces the greatest phase advance in DSWPD. A patient with DLMO at 02:00 should receive light therapy around 10:00 initially, then move the session earlier by 15 to 30 minutes per day as phase advances. [17]

Repeat Testing

Retesting 6 to 8 weeks into a phase-advancing protocol confirms whether DLMO has shifted. In most DSWPD treatment protocols, clinicians expect 30 to 60 minutes of DLMO advance per month of combined melatonin and phototherapy. Patients who show <20 minutes of advance at 8 weeks may have a genetic variant in CRY1 or PERIOD3, and genomic testing should be considered. [18]

The American Academy of Sleep Medicine's 2015 Clinical Practice Guideline on circadian rhythm sleep-wake disorders (AASM Guideline) states: "We recommend clinicians use strategically timed melatonin for the treatment of DSWPD (STRONG)." [19] That recommendation depends entirely on knowing when DLMO occurs.

Selecting a Laboratory

Not every hormone lab offers a validated salivary melatonin profile. The following features distinguish a reliable assay from a low-quality one.

Assay Sensitivity and Linearity

The assay's lower limit of detection (LLOD) must be 0.5 pg/mL or below. Melatonin concentrations in saliva at midday (the daytime nadir) can fall below 1 pg/mL, and an assay with an LLOD of 3 pg/mL cannot distinguish a daytime nadir from a pathologically blunted evening rise. Insist on the lab's assay performance data sheet before ordering.

Sample Stability Validation

A reputable lab publishes data showing that frozen (-20°C) salivary melatonin is stable for at least 6 months and that refrigerated samples (<4°C) are stable for 72 hours. Degradation during shipping is a frequent source of false-low results.

CLIA Certification

All clinical melatonin assays performed in the United States must be conducted in a CLIA-certified laboratory. Patients ordering direct-to-consumer tests should verify CLIA certification numbers before submitting samples. The FDA oversees CLIA through CMS; a searchable database is available at the FDA's CLIA pages.